A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Minocycline rescued synaptic abnormalities and improved behavior in the fragile X mouse model. Previous open-label human studies demonstrated benefits in individuals with fragile X syndrome (FXS); however, its efficacy in patients with FXS has not been assessed in a controlled trial. METHOD: Randomized, double-blind, placebo-controlled, crossover trial in individuals with FXS, aged 3.5 years to 16 years (n = 55, mean age 9.2 [SD, 3.6] years). Participants were randomized to minocycline or placebo for 3 months and then switched to the other treatment. RESULTS: Sixty-nine subjects were screened and 66 were randomized. Fifty-five subjects (83.3%) completed at least the first period and 48 (72.7%) completed the full trial. Intention-to-treat analysis demonstrated significantly greater improvements in one primary outcome, Clinical Global Impression Scale-Improvement after minocycline compared with placebo (2.49 ± 0.13 and 2.97 ± 0.13, respectively, p = .0173) and greater improvement in ad hoc analysis of anxiety and mood-related behaviors on the Visual Analog Scale (minocycline: 5.26 cm ± 0.46 cm, placebo: 4.05 cm ± 0.46 cm; p = .0488). Side effects were not significantly different during the minocycline and placebo treatments. No serious adverse events occurred on minocycline. Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding, and preliminary efficacy analysis results known to investigators. CONCLUSIONS: Minocycline treatment for 3 months in children with FXS resulted in greater global improvement than placebo. Treatment for 3 months appears safe; however, longer trials are indicated to further assess benefits, side effects, and factors associated with a clinical response to minocycline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduction of MMP-9 levels with minocycline in humans with FXS (Dziembowska et al., 2013) contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS (Paribello et al., 2010; Leigh et al., 2013; Schneider et al., 2013).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Leigh et al., 2013
Experimental — accuracy not yet measuredIn the citing paper
“In a randomized double-blind, placebo-controlled trial in children and adolescents with FXS, three months of minocycline treatment improved anxiety and mood-related behaviours238.”
From Immune mediators in the brain and peripheral tissues in autism spectrum disorder (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wechsler Abbreviated Scale of Intelligence
Dumont, R., Willis, J. O., Veizel, K., & Zibulsky, J. (2014) · Encyclopedia of Special Education · doi:10.1002/9781118660584.ese2519 · Cited by 5,521
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Dumont, R., & Willis, J. O. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0804 · Cited by 946
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
Research works printed but not linked: 1
- Sparrow SS Cicchetti DV Balla DA Vineland Adaptive Behavior Scales 2005 American Guidance Service Circle Pines Second Edition
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationGenetic studies in intellectual disability and related disorders
Vissers, L. E. L. M., Gilissen, C., & Veltman, J. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg3999 · Cited by 761
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Immune mediators in the brain and peripheral tissues in autism spectrum disorder
Estes, M. L., & McAllister, A. K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3978 · Cited by 514
Conflicts of interest: none declared
Suga, H., Eto, H., Inoue, K., Aoi, N., Kato, H., Araki, J., Higashino, T., Yoshimura, K., Yoshimura, K., Publication, A. F., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0007 · Cited by 442
MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 382
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationNaviaux, J. C., Wang, L., Li, K., Bright, A., Alaynick, W. A., Williams, K. R., Powell, S. B., & Naviaux, R. K. (2015) · Molecular Autism · doi:10.1186/2040-2392-6-1 · Cited by 285
“Minocycline has also shown benefit in both human Fragile X syndrome [61] and mouse models [62].”
BackgroundDysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275
“Minocycline has also been reported to have success in ameliorating symptoms in individuals with FXS 98 .”
BackgroundDisruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions
Nussbacher, J. K., Tabet, R., Yeo, G. W., & Lagier-Tourenne, C. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.014 · Cited by 272
Metformin ameliorates core deficits in a mouse model of fragile X syndrome
Gantois, I., Khoutorsky, A., Popic, J., Aguilar-Valles, A., Freemantle, E., Cao, R., Sharma, V., Pooters, T., Nagpal, A., Skalecka, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4335 · Cited by 228
Reinhard, S. M., Razak, K., & Ethell, I. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00280 · Cited by 219
Chen, C., Jiang, P., Xue, H., Peterson, S. E., Tran, H. T., McCann, A. E., Parast, M. M., Li, S., Pleasure, D. E., Laurent, L. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms5430 · Cited by 219
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207
Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.064 · Cited by 201
“High plasma activity of MMP-9 was reported in individuals with FXS (Dziembowska et al., 2013; Leigh et al., 2013), whereas elevated protein amounts of MMP-9 were detected in amniotic fluid from ASD mothers (Abdallah et al., 2012).”
BackgroundRojas, D. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1216-0 · Cited by 191
“It is also of interest that minocycline may have positive effects on mood and anxiety symptoms (Soczynska et al. 2012; Leigh et al. 2013) since these symptoms, although not considered core deficits in autism, are common in people on the spectrum (Mazefsky et al. 2008).”
BackgroundFragile X–associated tremor/ataxia syndrome
Hagerman, P. J., & Hagerman, R. J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12693 · Cited by 172
Self-citationThe Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 165
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161
Self-citationFragile X syndrome: a review of clinical and molecular diagnoses
Ciaccio, C., Fontana, L., Milani, D., Tabano, S., Miozzo, M., & Esposito, S. (2017) · Italian Journal of Pediatrics · doi:10.1186/s13052-017-0355-y · Cited by 160
“It is currently under study for FXS treatment and seems to have its greatest effect in young children, where it strengthens synaptic connections and enhances cognitive development [96].”
BackgroundUpdated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry-Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 157
Self-citationFragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 154
Self-citationSidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1162-14.2014 · Cited by 155
“Minocycline promotes dendritic spine maturation and improves FXS-associated behaviors in both Fmr1 ko mice and FXS subjects (Bilousova et al., 2009; Paribello et al., 2010; Rotschafer et al., 2012; Dansie et al., 2013; Leigh et al., 2013; Schneider et al., 2013).”
BackgroundSensory Processing Phenotypes in Fragile X Syndrome
Rais, M., Binder, D. K., Razak, K. A., & Ethell, I. M. (2018) · ASN Neuro · doi:10.1177/1759091418801092 · Cited by 130
“…minocycline, which beside its antibiotic effects inhibits MMP-9, has emerged as a potential treatment for FXS (Bilousova et al., 2009; Paribello et al., 2010; Dansie et al., 2013; Dziembowska et al., 2013; Leigh et al., 2013; Schneider et al., 2013; Rotschafer & Razak, 2014; Yau et al., 2018).”
BackgroundFragile X syndrome: An overview and update of the FMR1 gene
Milà, M., Álvarez‐Mora, M. I., Madrigal, I., & Rodríguez‐Revenga, L. (2017) · Clinical Genetics · doi:10.1111/cge.13075 · Cited by 164
“Finally, promising pre-clinical results have been obtained with the administration of lovastatin, cannabinoids, omega-3 and other neutraceuticals.(79) Despite all target-based treatments tested, at present the treatment of FXS is supportive and depends on the symptoms presented, with”
BackgroundGreen, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 127
“Clinical Global Impression Scale (CGI) but not on any behavioural measures (Leigh et al., 2013).”
InfluentialThe challenges of clinical trials in fragile X syndrome
Jacquemont, S., Berry-Kravis, E., Hagerman, R., von Raison, F., Gasparini, F., Apostol, G., Ufer, M., Des Portes, V., & Gomez-Mancilla, B. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3289-0 · Cited by 125
“2012); and minocycline, a matrix metalloproteinase-9 antagonist (Bilousova et al. 2009; Leigh et al. 2013; Paribello et al. 2010; Utari et al. 2010).”
InfluentialSelf-citationMcDiarmid, T. A., Bernardos, A. C., & Rankin, C. H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.028 · Cited by 133
“…antibiotic minocycline has recently been shown to increase global functioning, improve performance on tests of anxiety and mood-related behaviours, as well as ameliorate EEG-recorded sensory abnormalities and reduced habituation in individuals with FXS (Leigh et al., 2013; Schneider et al., 2013).”
Saldarriaga, W., Tassone, F., González-Teshima, L. Y., Forero-Forero, J. V., Ayala-Zapata, S., & Hagerman, R. (2014) · Colombia Medica · doi:10.25100/cm.v45i4.1810 · Cited by 122
Self-citationAsadi, A., Abdi, M., Kouhsari, E., Panahi, P., Sholeh, M., Sadeghifard, N., Amiriani, T., Ahmadi, A., Maleki, A., & Gholami, M. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.01.022 · Cited by 124
Fragile X Syndrome: from molecular pathology to therapy
Maurin, T., Zongaro, S., & Bardoni, B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.006 · Cited by 113
Saldarriaga, W., Tassone, F., González-Teshima, L. Y., Forero-Forero, J. V., Ayala‐Zapata, S., & Hagerman, R. J. (2014) · PubMed Central · Cited by 159
Self-citationThe Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses.
Janusz, A., Miłek, J., Perycz, M., Pacini, L., Bagni, C., Kaczmarek, L., & Dziembowska, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2207-13.2013 · Cited by 112
“Based on those findings clinical trials to test minocycline have been undertaken and there is evidence that minocycline provides some functional benefits to FXS patients (Paribello et al., 2010; Utari et al., 2010; Leigh et al., 2013).”
BackgroundDrug discovery for autism spectrum disorder: challenges and opportunities
Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P., & Santarelli, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4102 · Cited by 108
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
“A pilot placebo-controlled crossover trial of minocycline, an antibiotic that inhibits overexpressed synaptic MMP-9 in FXS models, conducted in children with FXS demonstrated mild global clinical improvement and reduction of MMP-9 levels in the blood of responders [205].”
BackgroundFragile X Syndrome: From Molecular Aspect to Clinical Treatment
Protic, D. D., Aishworiya, R., Salcedo‐Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041935 · Cited by 118
Self-citationBailey, D. B., Berry-Kravis, E., Wheeler, A., Raspa, M., Merrien, F., Ricart, J., Koumaras, B., Rosenkranz, G., Tomlinson, M., von Raison, F., et al. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9134-5 · Cited by 101
“These scales were also used as the primary outcome measure in a randomized, double-blind, placebo-controlled trial of minocycline in children and adolescents with FXS [20], in which a marginal but statistically significant (p = 0.”
MethodLong-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95
Minocycline in neurodegenerative and psychiatric diseases: An update
Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2021) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 93
Santos, A. R., Kanellopoulos, A. K., & Bagni, C. (2014) · Learning & Memory · doi:10.1101/lm.035956.114 · Cited by 86
“Finally, minocycline administration in patients with FXS was shown to improve attention deficits, language use, and communication skills (Paribello et al. 2010; Utari et al. 2010; Leigh et al. 2013).”
BackgroundDrug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 97
“Encouragement for development and testing of other ERPs is found in the negative FXS controlled minocycline trial (Leigh et al., 2013), where a subset of participants showed improved habituation to auditory stimulation (Schneider et al.”
MethodNeul, J. L., Glaze, D. G., Percy, A. K., Feyma, T., Beisang, A., Dinh, T., Suter, B., Anagnostou, E., Snape, M., Horrigan, J., et al. (2015) · Journal of Child Neurology · doi:10.1177/0883073815579707 · Cited by 85
“It has been widely used as an outcome measure in central nervous system clinical trials, including trials in neurodevelopmental disorders such as autism and Fragile X syndrome.(13,14) The Clinical Global Impression Scale is a 7-point Likert-type rating scale that reflects expert clinical judgment.”
MethodMatrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines
Stawarski, M., Stefaniuk, M., & Wlodarczyk, J. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00068 · Cited by 84
“Notably, minocycline has been tested in clinical trials to treat fragile X syndrome and shown to provide significant functional benefits (Paribello et al., 2010; Utari et al., 2010; Leigh et al., 2013).”
BackgroundDoll, C. A., & Broadie, K. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00030 · Cited by 88
“…and attention in FXS patients in an uncontrolled study (Utari et al., 2010), and a recent 3-month double-blind, placebo-controlled trial with young FXS patients showed improvements in anxiety, mood, and clinical global impression (CGI) of FXS individuals given minocycline (Leigh et al., 2013).”
BackgroundMechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome
Berry‐Kravis, E. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.001 · Cited by 96
Pharmacotherapy for mental health problems in people with intellectual disability
Ji, N. Y., & Findling, R. L. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000233 · Cited by 88
“[127– 138] A recent RPCT in boys with FXS reported that minocycline was effective in improving problem behaviors associated with ADHD and anxiety.[131]”
BackgroundMethodNeural ECM proteases in learning and synaptic plasticity
Tsilibary, E. C., Tzinia, A. K., Radenović, L., Stamenković, V., Lebitko, T., Mucha, M. W., Pawlak, R., Frischknecht, R., & Kaczmarek, L. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63486-3.00006-2 · Cited by 79
Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia: Table 1.
Lepeta, K., & Kaczmarek, L. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv036 · Cited by 74
Transient ECM protease activity promotes synaptic plasticity
Magnowska, M., Gorkiewicz, T., Suska, A., Wawrzyniak, M., Rutkowska-Wlodarczyk, I., Kaczmarek, L., & Wlodarczyk, J. (2016) · Scientific Reports · doi:10.1038/srep27757 · Cited by 73
Quartier, A., Poquet, H., Gilbert‐Dussardier, B., Rossi, M., Casteleyn, A.-S., Portes, V. D., Feger, C., Nourisson, E., Kuentz, P., Redin, C. E., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.204 · Cited by 78
Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 69
“These ‘second generation’ trials attempt to avoid pitfalls potentially related to the aforementioned negative results by enrolling younger patients, using objective cognitive measures and biomarkers including EEG and eye tracking (40,41).”
BackgroundSelf-citationCharacterizing autism spectrum disorders by key biochemical pathways
Subramanian, M., Timmerman, C. K., Schwartz, J. L., Pham, D. L., & Meffert, M. K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00313 · Cited by 73
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Thurman, A. J., McDuffie, A., Hagerman, R., & Abbeduto, L. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.01.032 · Cited by 70
Self-citationModulation of the GABAergic pathway for the treatment of fragile X syndrome
Hagerman, R., Lozano, R., & Hare, E. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42919 · Cited by 65
“…be effective at an early age is minocycline, which is an antibiotic that lowers the level of matrix metalloproteinase 9 which is elevated in FXS. 81,82 High levels of matrix metalloproteinase 9 interfere with the development of synaptic connections, and a controlled trial of minocycline in…”
BackgroundSelf-citationNeuroinflammatory alterations in trait anxiety: modulatory effects of minocycline
Rooney, S., Sah, A., Unger, M. S., Kharitonova, M. V., Sartori, S. B., Schwarzer, C., Aigner, L., Kettenmann, H., Wolf, S. A., & Singewald, N. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00942-y · Cited by 72
Metformin treatment in young children with fragile X syndrome
Biag, H. M. B., Potter, L. A., Wilkins, V., Afzal, S., Rosvall, A., Salcedo‐Arellano, M. J., Rajaratnam, A., Manzano‐Nunez, R., Schneider, A., Tassone, F., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.956 · Cited by 68
Self-citationPublic Health Literature Review of Fragile X Syndrome
Raspa, M., Wheeler, A., & Riley, C. M. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159c · Cited by 75
Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins
Chen, E., & Joseph, S. (2015) · Biochimie · doi:10.1016/j.biochi.2015.02.005 · Cited by 74
“Additionally, a drug trial is underway to use minocycline, an analogue of the tetracycline antibiotic, to treat children with FXS (Leigh et al., 2013).”
BackgroundSize and methylation mosaicism in males with Fragile X syndrome
Jiraanont, P., Kumar, M., Tang, H.-T., Espinal, G. M., Hagerman, P. J., Hagerman, R. J., Chutabhakdikul, N., & Tassone, F. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1377612 · Cited by 69
“a trial of minocycline to assess its benefit as a targeted treatment for FXS [65].”
BackgroundSelf-citationFragile X syndrome and fragile X-associated tremor ataxia syndrome
Hall, D. A., & Berry‐Kravis, E. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00025-7 · Cited by 69
Tetracyclines Modify Translation By Targeting Key Human rRNA Substructures
Mortison, J. D., Schenone, M., Myers, J. A., Zhang, Z., Chen, L., Ciarlo, C., Comer, E. J., Natchiar, S. K., Carr, S. A., Klaholz, B. P., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.09.010 · Cited by 64
Chakraborty, P., Dey, A., Gopalakrishnan, A. V., Swati, K., Ojha, S. K., Prakash, A., Kumar, D., Ambasta, R. K., Jha, N. K., Jha, S. K., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101838 · Cited by 68
Fragile X syndrome: clinical presentation, pathology and treatment
Salcedo‐Arellano, M. J., Hagerman, R. J., & Martínez‐Cerdeño, V. (2019) · Gaceta Médica de México · doi:10.24875/gmm.19005275 · Cited by 80
Self-citationGhaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0175 · Cited by 55
“Interestingly, both animal studies on the FXS rat model (Bilousova et al. 2009) and clinical trials on patients with FXS have shown minocycline to be effective and safe in improving behavioral function (Paribello et al. 2010; Leigh et al. 2013).”
Dalhoff, A. (2020) · Infection · doi:10.1007/s15010-020-01536-y · Cited by 64
Thurman, A. J., Potter, L. A., Kim, K., Tassone, F., Banasik, A., Potter, S. N., Bullard, L., Nguyen, V., McDuffie, A., Hagerman, R., et al. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09315-4 · Cited by 58
Self-citationTartaglia, N. R., Bonn‐Miller, M. O., & Hagerman, R. J. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0053 · Cited by 64
Self-citationMinocycline protects the immature white matter against hyperoxia
Schmitz, T., Krabbe, G., Weikert, G., Scheuer, T., Matheus, F., Wang, Y., Mueller, S. G., Kettenmann, H., Matyash, V., Bührer, C., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.01.017 · Cited by 60
New Targeted Treatments for Fragile X Syndrome
Protic, D. D., Salcedo‐Arellano, M. J., Dy, J. B. S., Potter, L. A., & Hagerman, R. J. (2019) · Current Pediatric Reviews · doi:10.2174/1573396315666190625110748 · Cited by 60
Self-citationDíaz-Caneja, C., State, M., Hagerman, R., Jacquemont, S., Marín, O., Bagni, C., Umbricht, D., Simonoff, E., de Andrés-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 55
Self-citationNeural Correlates of Auditory Hypersensitivity in Fragile X Syndrome
Razak, K. A., Binder, D. K., & Ethell, I. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720752 · Cited by 61
“A randomized placebocontrolled study of minocycline showed improvement in Clinical Global Impression Scale compared to placebo and greater improvement in anxiety and mood-related behaviors on the Visual Analog Scale (98).”
MethodFragile X syndrome: From targets to treatments
Wijetunge, L. S., Chattarji, S., Wyllie, D. J. A., & Kind, P. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.028 · Cited by 67
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
Fragile X syndrome and fragile X-associated disorders
Rajaratnam, A., Shergill, J., Salcedo‐Arellano, M. J., Saldarriaga, W., Duan, X., & Hagerman, R. J. (2017) · F1000Research · doi:10.12688/f1000research.11885.1 · Cited by 61
Self-citationTreatment of the psychiatric problems associated with fragile X syndrome
Hagerman, R. J., & Polussa, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000131 · Cited by 58
Self-citationFrom FMRP Function to Potential Therapies for Fragile X Syndrome
Sethna, F., Moon, C., & Wang, H. (2014) · Neurochemical Research · doi:10.1007/s11064-013-1229-3 · Cited by 47
“A double blind, placebo-controlled, crossover trial with minocycline treatment in FXS children resulted in improvements in anxiety and mood-related behavior [163].”
BackgroundPitkänen, A., Ndode‐Ekane, X. E., Łukasiuk, K., Wilczynski, G. M., Dityatev, A. E., Walker, M. C., Chabrol, E., Dedeurwaerdere, S., Vázquez, N., & Powell, E. M. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63486-3.00011-6 · Cited by 55
Nakai, N., Takumi, T., Nakai, J., & Sato, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00412 · Cited by 52
Targeted treatments in autism and fragile X syndrome
Gürkan, C. K., & Hagerman, R. J. (2012) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2012.05.007 · Cited by 44
Self-citationEmerging pharmacologic treatment options for fragile X syndrome
Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 50
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis
Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133316 · Cited by 43
“As there were three studies with clearly higher effect size than the rest ([38, 40, 45]), we tested if the placebo meta-analysis would still be significant with them removed.”
BackgroundThe Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Castagnola, S., Bardoni, B., & Maurin, T. (2017) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2017.00015 · Cited by 40
“Until now, minocycline has been shown to be successful in two different clinical trials (Paribello et al., 2010; Leigh et al., 2013) and, importantly, treatment with mynocline resulted in the improvement of some event-related potentials compared with placebo (Schneider et al., 2013).”
ResultA Spoken-Language Intervention for School-Aged Boys With Fragile X Syndrome
McDuffie, A., Machalicek, W., Bullard, L., Nelson, S., Mello, M., Tempero-Feigles, R., Castignetti, N., & Abbeduto, L. (2016) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-121.3.236 · Cited by 41
AlOlaby, R. R., Sweha, S. R., Silva, M., Durbin-Johnson, B., Yrigollen, C. M., Pretto, D., Hagerman, R. J., & Tassone, F. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.01.012 · Cited by 41
Self-citationRepurposing available drugs for neurodevelopmental disorders: The fragile X experience
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R., Guilliams, T., & Cogram, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 39
“Subsequent studies in the Drosophila model of fragile X confirmed the therapeutic potential of minocycline (Siller and Broadie, 2011), leading to a positive open label clinical trial (Paribello et al., 2010) andmodestly positive effects in a placebo controlled trial (Leigh et al., 2013).”
BackgroundResponse to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
Luu, S., Province, H. S., Berry‐Kravis, E., Hagerman, R. J., Hessl, D. R., Vaidya, D. M., Lozano, R., Rosselot, H., Erickson, C. A., Kaufmann, W. E., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10090629 · Cited by 42
“Out of the four studies that had CGI data, three of them included children [23,27,28] and three included adolescents/adults [23,26,27].”
BackgroundSelf-citationEmpowerment in decision-making for autistic people in research
Cascio, M. A., Weiss, J. A., & Racine, É. (2020) · Disability & Society · doi:10.1080/09687599.2020.1712189 · Cited by 41
“In keeping with the individualization guidepost of personoriented research ethics (Cascio & Racine 2018), the consent process can also be individualized to the unique needs of each person in certain ways (Cridland et al. 2015; Carlson 2013; Howe 2003; Cermak et al. 2015; Leigh et al. 2013).”
BackgroundMinocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00771 · Cited by 43
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38
Self-citationNew innovations: Therapeutic opportunities for intellectual disabilities
Picker, J. D., & Walsh, C. A. (2013) · Annals of Neurology · doi:10.1002/ana.24002 · Cited by 34
“that seems to have an inhibitory effect on the mGluR5 receptor, appeared in a double-blind study to have some efficacy.(51,52)”
EEG as a translational biomarker and outcome measure in fragile X syndrome
Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 38
“This trend towards inconsistency has been observed in other common measures including the Social Responsiveness Scale (measuring social impairment), the Clinical Global Impression, severity and improvement scales (CGI-S, CGI-I) (measuring symptom severity or improvement respectively) and the Visual Analogue Scale (VAS…”
MethodMolecular Biomarkers in Fragile X Syndrome
Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 38
“More recently, a controlled double-blind crossover study of minocycline for FXS treatment provided evidence for the safety of minocycline and showed benefits in global functioning in children with FXS [155].”
BackgroundSelf-citationFragile X syndrome neurobiology translates into rational therapy
Braat, S., & Kooy, R. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.013 · Cited by 37
Auditory hypersensitivity and processing deficits in a rat model of fragile X syndrome
Auerbach, B. D., Manohar, S., Radziwon, K. E., & Salvi, R. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105541 · Cited by 36
The promising trajectory of autism therapeutics discovery
Silverman, J. L., & Crawley, J. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.007 · Cited by 40
Delivery Systems as Vital Tools in Drug Repurposing
Czech, T., Lalani, R., & Oyewumi, M. O. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1333-z · Cited by 36
Pharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport, M. H., Schaefer, T. L., Friedmann, K., Fitzpatrick, S. E., & Erickson, C. A. (2016) · Drugs · doi:10.1007/s40265-016-0542-y · Cited by 35
Metadata
- Authors
- Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., Hessl, D., & Hagerman, R. J.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Diponegoro University (ID)
- Corresponding author
- Leigh, Mary Jacena S.
- Schneider, Andrea
- Chechi, Tasleem
- Polussa, Jonathan
- Hessl, David
- Hagerman, Randi J.
- ORCID
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-04
- Volume
- 34
- Issue
- 3
- Pages
- 147-155
- ISSN
- 0196-206X (ISSN-L)
- PMC
- PMC3706260
- OpenAlex
- W2159857276
- Cited by
- 298
- References
- 37
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 18 · 2021: 10 · 2020: 48 · 2019: 21 · 2018: 19 · 2017: 35 · 2016: 40 · 2015: 28 · 2014: 32 · 2013: 15
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Developmental & Behavioral Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000002)
- University of California, Davis
- National Institute of Mental Health (T32MH073124)
- National Center for Research Resources (UL1RR024146)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 02274, P30HD002274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- minocycline, fragile X syndrome, children and adolescents, anxiety, mood, Clinical Global Impression Scale, treatment efficacy, drug safety, synaptic abnormalities
- MeSH terms
- Adolescent, Child, Child, Preschool, Double-Blind Method, Female, Fragile X Syndrome, Humans, Intelligence, Male, Minocycline, Psychiatric Status Rating Scales, Psychological Tests, Treatment Outcome, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.